99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of NVCN Investors. Click "Join this Class Action" above.

Attorneys

Neovasc Inc.

Join Class Action »

Zhang Investor Law announces  a class action lawsuit on behalf of shareholders who bought shares of Neovasc Inc. (NASDAQ: NVCN) from November 1, 2019 through October 27, 2020 (the “Class Period”). The lawsuit seeks to recover damages for Neovasc Inc. investors under the federal securities laws.

If you bought Neovasc Inc. securities between November 1, 2019 through October 27, 2020, and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Neovasc Inc. – NVCN

New York, N.Y., November 13, 2020. Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Neovasc Inc. (NASDAQ: NVCN) between November 1, 2019 and October 27, 2020, inclusive (the “Class Period”).

To join the NVCN class action, go to http://zhanginvestorlaw.com/cases/neovasc-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.

According to the lawsuit,  throughout the Class Period (1) the results of COSIRA, Neovasc’s clinical study for the Reducer, contained imbalances in missing information present in the control group versus the treatment group, including significant missing information for secondary endpoints but none for the primary endpoint; (2) the imbalance in missing information indicated that control subjects were aware of their treatment assignment (not blinded) and less inclined to participate in additional data collection; (3) blinding is critical when studying a placebo-responsive condition such as angina; (4) the lack of blinding assessment made the primary endpoint difficult to interpret; (5) as a result of the foregoing, the FDA was reasonably likely to require additional premarket clinical data; (6) as a result, the Company’s Premarket Approval application (PMA) for Reducer was unlikely to be approved without additional clinical data; and (7) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 5, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/neovasc-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.